Cigdem Korkmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cigdem Korkmaz has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Ayse Ayzit Kilinc
Department of Pediatric Pulmonology, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Türkiye
4 shared publications - Berrak Oztosun
Department of Pediatric Pulmonology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
3 shared publications - Abdurrahman Zarif Güney
Department of Pediatric Pulmonology Istanbul University‐Cerrahpasa, Cerrahpasa Faculty of Medicine Istanbul Turkiye
2 shared publications - Furkan Yilmaz
Department of Pediatric Pulmonology Istanbul University‐Cerrahpasa, Cerrahpasa Faculty of Medicine Istanbul Turkiye
2 shared publications Abdulhamit Colak
Department of Pediatric Pulmonology Istanbul University‐Cerrahpasa, Cerrahpasa Faculty of Medicine Istanbul Turkiye
1 shared publication- Abdulhamit Çollak
Division of Pediatric, Bezmilalem Vakif University, İstanbul, Turkey
1 shared publication
Latest Publications
- 12 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Multiparametric ultrasound characterizes pediatric cystic fibrosis hepatobiliary involvement
Objectives: The contemporary European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) framework broadens the definition of cystic fibrosis hepatobiliary involvement (CFHBI), but the biological interpretation of individual multiparametric ultrasound parameters within this framework remains unclear. We evaluated the biological associations of shear wave elastography (SWE), shear wave dispersion (SWD), and attenuation imaging (ATI) with histopathological phenotypes in children with cystic fibrosis (CF). Methods: In this ambispective cohort study, 119 children with CF underwent hepatobiliary assessment, including SWE, SWD, ATI, Doppler ultrasonography, clinical and laboratory evaluation. Histopathological assessment was performed when clinically indicated. CFHBI was classified according to the ESPGHAN/NASPGHAN framework, with the Debray criteria used as a secondary exploratory comparison. Exploratory phenotype‐oriented analyses evaluated ultrasound parameters according to corresponding histopathological phenotypes. Results: Exploratory phenotype‐oriented analyses demonstrated significantly higher ATI values in histopathologically defined steatosis ( p < 0.001), with good discriminatory performance (AUC 0.813) and an optimal threshold of 0.655 dB/cm/MHz. In contrast, SWE was not associated with histopathologically defined fibrosis ( p = 0.151), whereas SWD showed no significant phenotype‐specific associations. Secondary exploratory analyses demonstrated significant overall CFHBI discrimination by all three ultrasound parameters, with the highest AUC observed for SWD. The ESPGHAN/NASPGHAN and Debray classifications demonstrated significant disagreement (McNemar p < 0.001), with 22.7% of patients classified as Debray‐negative but ESPGHAN/NASPGHAN‐positive. Conclusions: Multiparametric ultrasound should be interpreted within the contemporary ESPGHAN/NASPGHAN CFHBI framework rather than as a single diagnostic tool for hepatobiliary involvement. The distinct biological associations of SWE, ATI, and SWD support a phenotype‐oriented interpretation of individual ultrasound parameters, whereas overall CFHBI discrimination should be interpreted as a secondary exploratory finding requiring prospective multicenter validation.
- 12 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Multiparametric ultrasound characterizes pediatric cystic fibrosis hepatobiliary involvement
Objectives: The contemporary European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) framework broadens the definition of cystic fibrosis hepatobiliary involvement (CFHBI), but the biological interpretation of individual multiparametric ultrasound parameters within this framework remains unclear. We evaluated the biological associations of shear wave elastography (SWE), shear wave dispersion (SWD), and attenuation imaging (ATI) with histopathological phenotypes in children with cystic fibrosis (CF). Methods: In this ambispective cohort study, 119 children with CF underwent hepatobiliary assessment, including SWE, SWD, ATI, Doppler ultrasonography, clinical and laboratory evaluation. Histopathological assessment was performed when clinically indicated. CFHBI was classified according to the ESPGHAN/NASPGHAN framework, with the Debray criteria used as a secondary exploratory comparison. Exploratory phenotype‐oriented analyses evaluated ultrasound parameters according to corresponding histopathological phenotypes. Results: Exploratory phenotype‐oriented analyses demonstrated significantly higher ATI values in histopathologically defined steatosis ( p < 0.001), with good discriminatory performance (AUC 0.813) and an optimal threshold of 0.655 dB/cm/MHz. In contrast, SWE was not associated with histopathologically defined fibrosis ( p = 0.151), whereas SWD showed no significant phenotype‐specific associations. Secondary exploratory analyses demonstrated significant overall CFHBI discrimination by all three ultrasound parameters, with the highest AUC observed for SWD. The ESPGHAN/NASPGHAN and Debray classifications demonstrated significant disagreement (McNemar p < 0.001), with 22.7% of patients classified as Debray‐negative but ESPGHAN/NASPGHAN‐positive. Conclusions: Multiparametric ultrasound should be interpreted within the contemporary ESPGHAN/NASPGHAN CFHBI framework rather than as a single diagnostic tool for hepatobiliary involvement. The distinct biological associations of SWE, ATI, and SWD support a phenotype‐oriented interpretation of individual ultrasound parameters, whereas overall CFHBI discrimination should be interpreted as a secondary exploratory finding requiring prospective multicenter validation.
- 9 October 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (11) , 826
Obstructive sleep apnoea severity and insulin resistance in children with Prader–Willi Syndrome: the SPISE index as a candidate metabolic marker
- 9 October 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (11) , 826
Obstructive sleep apnoea severity and insulin resistance in children with Prader–Willi Syndrome: the SPISE index as a candidate metabolic marker
- 14 August 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (8)
Interstitial Lung Disease in Children: Rare Genetic Variants Beyond Surfactant Dysfunction
Background: Advances in genetic analysis techniques and strategies have enabled the identification of rare novel genetic entities in children's interstitial lung disease (chILD). Aims: To describe an extensive array of demographic, clinical, radiological, and laboratory data from a national registry of children with diffuse lung disease caused by rare and novel genetic variants. Study Design: Retrospective cohort study. Methods: This study used data from the chILD Türkiye (chILD‐TR) registry to analyze rare genetic chILD subtypes, excluding surfactant protein gene variants, ABCA3 , and NKX2‐1 , between November 2021 and January 2024. Of 671 patients in chILD‐TR, 182 underwent genetic analysis excluding surfactant protein‐related variants, resulting in 37 patients identified with rare genetic variants included in the study. Results: Among the 37 patients with rare genetic variants, 19 (51.4%) were male, and the median age at diagnosis was 40.5 months (IQR 15.5–115.5). Genetic analysis conducted on 15 patients identified COPA , STAT3 , STING1 , ADA , ZNFX1 , PIK3CD , PLCG2 , OAS1, CCR2, RNF168 and ATM gene variants, which are associated with immunodeficiency/dysregulation and autoinflammation; 15 NPC1 , SMPD1 , GBA1 , SLC7A7 , MARS1 , FARSB , and PEPD genes, variants linked to inherent metabolic errors. Seven patients were found with TBX4 , SLC34A2 , PLG , and SMAD4 gene variants. All patients were born at term, and five (13.5%) of them were small for gestational age. Two patients (5.4%) had previously been on a mechanical ventilator in the neonatal intensive care unit, 25(67.6%) had familial consanguinity, and 23 (62.1%) had comorbid systemic disease. Thirteen patients (35.1%) required oxygen support. All patients underwent chest computed tomography scans at initial assessment, showing ground‐glass opacities in 29 (78.3%), infiltrations in 27 (72.9%), and interlobular septal thickening in 20 (54%). Eight patients (21.6%) received oral steroids, and six (16.2%) received pulse steroids in addition to their primary treatments for systemic diseases. Conclusions: Interstitial lung disease rarely occurs in children, but increased awareness and genetic testing may enable earlier diagnosis. Recognizing that diffuse parenchymal lung disease can occur in rare systemic diseases may improve diagnoses and treatment.
- 14 August 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (8)
Interstitial Lung Disease in Children: Rare Genetic Variants Beyond Surfactant Dysfunction
Background: Advances in genetic analysis techniques and strategies have enabled the identification of rare novel genetic entities in children's interstitial lung disease (chILD). Aims: To describe an extensive array of demographic, clinical, radiological, and laboratory data from a national registry of children with diffuse lung disease caused by rare and novel genetic variants. Study Design: Retrospective cohort study. Methods: This study used data from the chILD Türkiye (chILD‐TR) registry to analyze rare genetic chILD subtypes, excluding surfactant protein gene variants, ABCA3 , and NKX2‐1 , between November 2021 and January 2024. Of 671 patients in chILD‐TR, 182 underwent genetic analysis excluding surfactant protein‐related variants, resulting in 37 patients identified with rare genetic variants included in the study. Results: Among the 37 patients with rare genetic variants, 19 (51.4%) were male, and the median age at diagnosis was 40.5 months (IQR 15.5–115.5). Genetic analysis conducted on 15 patients identified COPA , STAT3 , STING1 , ADA , ZNFX1 , PIK3CD , PLCG2 , OAS1, CCR2, RNF168 and ATM gene variants, which are associated with immunodeficiency/dysregulation and autoinflammation; 15 NPC1 , SMPD1 , GBA1 , SLC7A7 , MARS1 , FARSB , and PEPD genes, variants linked to inherent metabolic errors. Seven patients were found with TBX4 , SLC34A2 , PLG , and SMAD4 gene variants. All patients were born at term, and five (13.5%) of them were small for gestational age. Two patients (5.4%) had previously been on a mechanical ventilator in the neonatal intensive care unit, 25(67.6%) had familial consanguinity, and 23 (62.1%) had comorbid systemic disease. Thirteen patients (35.1%) required oxygen support. All patients underwent chest computed tomography scans at initial assessment, showing ground‐glass opacities in 29 (78.3%), infiltrations in 27 (72.9%), and interlobular septal thickening in 20 (54%). Eight patients (21.6%) received oral steroids, and six (16.2%) received pulse steroids in addition to their primary treatments for systemic diseases. Conclusions: Interstitial lung disease rarely occurs in children, but increased awareness and genetic testing may enable earlier diagnosis. Recognizing that diffuse parenchymal lung disease can occur in rare systemic diseases may improve diagnoses and treatment.
- 10 June 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (7) , 575-580
Tuberculosis Diagnosis and Prevention in Children on Biological Treatment: Clinical Challenges and Considerations
Tuberculosis (TB) remains a major global health concern, especially for children with rheumatic diseases on biologic therapies. While these agents have improved disease management and quality of life, they also pose new challenges, mainly an increased risk of TB, particularly with tumor necrosis factor‑alpha (TNF‑α) inhibitors like infliximab, adalimumab, and etanercept. Since TNF‑α plays a crucial role in granuloma formation and controlling Mycobacterium TB, its inhibition can allow latent TB infection (LTBI) to develop into active disease. To reduce this risk, screening for LTBI before starting biologic therapy is highly recommended. However, accurately detecting LTBI in children—especially those who are immunosuppressed—remains challenging, as both the tuberculin skin test (TST) and interferon‑gamma release assays (IGRAs) have notable limitations in this context. Using both TST and IGRA together may improve case detection in selected pediatric populations. Preventive treatment for LTBI reduces the risk of developing active TB in patients receiving biologic therapies. Although non-anti-TNF therapies may offer a safer option in this regard, the evidence in pediatric patients is still limited. As the use of biologic and targeted therapies expands in children, further research is needed—especially on non-anti-TNF agents—to create internationally accepted guidelines and to optimize screening, diagnostics, and personalized prevention strategies.
- 10 June 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (7) , 575-580
Tuberculosis Diagnosis and Prevention in Children on Biological Treatment: Clinical Challenges and Considerations
Tuberculosis (TB) remains a major global health concern, especially for children with rheumatic diseases on biologic therapies. While these agents have improved disease management and quality of life, they also pose new challenges, mainly an increased risk of TB, particularly with tumor necrosis factor‑alpha (TNF‑α) inhibitors like infliximab, adalimumab, and etanercept. Since TNF‑α plays a crucial role in granuloma formation and controlling Mycobacterium TB, its inhibition can allow latent TB infection (LTBI) to develop into active disease. To reduce this risk, screening for LTBI before starting biologic therapy is highly recommended. However, accurately detecting LTBI in children—especially those who are immunosuppressed—remains challenging, as both the tuberculin skin test (TST) and interferon‑gamma release assays (IGRAs) have notable limitations in this context. Using both TST and IGRA together may improve case detection in selected pediatric populations. Preventive treatment for LTBI reduces the risk of developing active TB in patients receiving biologic therapies. Although non-anti-TNF therapies may offer a safer option in this regard, the evidence in pediatric patients is still limited. As the use of biologic and targeted therapies expands in children, further research is needed—especially on non-anti-TNF agents—to create internationally accepted guidelines and to optimize screening, diagnostics, and personalized prevention strategies.